Category: Our News

We’re delighted to announce that Fusion Genomics has been awarded $1 million to conduct a prospective clinical study evaluating its product: ONETest™. The project will be funded through our Quantum Leap program with support from Merck and will explore the improvement for diagnosis of respiratory tract infections. Fusion Genomics ONETest™ is a highly sensitive, cost-effective…

April 1st, 2020 – Update Regarding the Current SynergiQc Call for Projects – CQDM wishes to confirm to the Quebec biopharmaceutical community that its current SynergiQc Call for projects is maintained. More than ever, it is crucial to promote the discovery and development of safe products in order to prevent, diagnose and treat diseases, related or not…

Montréal, December 18, 2019 – CQDM congratulates Theratechnologies for reporting positive results on TH-1902, a docetaxel conjugate for the treatment of triple-negative breast cancer (TNBC), during the prestigious San Antonio Breast Cancer Symposium held on December 10-14 in San Antonio (Texas, USA). Theratechnologies also announced that the Food and Drug Administration (FDA) has approved the…

Presented by CQDM, Diazon Pharmaceuticals and Mitacs, the Gordon Shore Prize is awarded to new graduates whose doctoral thesis demonstrated their research excellence in the life science field. A 6-month postdoctoral internship of $24,000 will be offered to each of the awardees by the participating Quebec-based companies: Feldan Therapeutics, Kisoji Biotechnology, Ovensa Innovations and Repare…

Montreal, November 29, 2019 – The Chairman of the Scientific Advisory Board, Daniel Hétu, and the President and CEO of CQDM, Diane Gosselin, are pleased to announce the appointment of two new members to CQDM’s governance. Bernard Massie, former Director General, Human Health Therapeutics at the NRC, and Cameron Black, Executive Vice President, Discovery at Repare Therapeutics…

The project led by Michel Bouvier and Domain Therapeutics with the support of CQDM is awarded the RSRI Recognition Award at the ADRIQ Innovation Prize Gala Montreal, November 22, 2019 – CQDM is proud to announce that the project led by Michel Bouvier from the Institute for Research in Immunology and Cancer (IRIC) of the Université de…

Zealand Pharma’s acquisition of Encycle Therapeutics highlights the impact of CQDM’s early support on Canadian biotech company creation and success. Montreal, November 11th, 2019 – CQDM commends Encycle Therapeutics for their acquisition by Zealand Pharma (NASDAQ: ZEAL)[1]. CQDM is proud to have supported Encycle Therapeutics and its technology platform from the very beginning in partnership…

CQDM, the Canadian Cancer Society and Theratechnologies grant $1.7M to UQAM for the development of a new therapy targeting the most aggressive form of breast cancer Montreal, October 4, 2019. – CQDM, in partnership with the Canadian Cancer Society (CCS) and Theratechnologies, is proud to announce that it will be granting $1.7M to Université du…

New appointments to CQDM’s Board of Directors and Scientific Advisory Board Montreal, September 23, 2019 – The chairman of the Board of Directors, Richard Fajzel, and Diane Gosselin, President and CEO of CQDM, are very pleased to announce the appointment of four new members overseeing CQDM’s governance. Daniel Hétu, Managing Director of Lumira Ventures, Sarah Jenna,…

PARTENAR-IA, a funding initiative to support public-private AI-based research projects ! DEADLINE: OCTOBER 15th, 2019 Montreal, August 20th, 2019 – The PARTENAR-IA initiative aims to accelerate the design and development of Artificial Intelligence (AI) technologies applicable in the biopharmaceutical sector by participating in the funding of collaborative research projects carried out in a Quebec public research…